Notice

Error
  • Error loading feed data
  • Error loading feed data
  • Error loading feed data

PRCSG News

Abstracts  / Posters / Presentations

 

 

ACR Convergence 2020

November 5 - 9, 2020

Virtual meeting

 

JIA-ACR50 Response as a Predictor of Minimal Disease Activity in Patients Aged 2–17 Years With Polyarticular-Course JIA Treated With SC Abatacept. Ruperto N, Brunner H, Berman A, Avila-Zapata F, Horneff G, Alessio M, Becker M, Belot A, Burgos-Vargas R, Boteanu A, Goldenstein-Schainbert C, Scheibel I, Terreri M, Zemel L, Wong R, Askelson M, Nys M, Martini A, Lovell D.

 

Longitudinal Effectiveness of Abatacept in JIA: Results From an Ongoing JIA Registry. Lovell DJ, Brunner HI, Tzaribachev N, Morgan E, Simonini G, Griffin TA, Alexeeva E, Bohnsack J, Zeft A, Horneff G, Vehe R, Stanevica V, Tarvin S, Trachana M, Huber A, Orban I, Dare J, Foeldvari I, Quartier P, Dominique A, Kou TD.

 

  ************************************************************************************************************************

September 2020 - FDA Approves Simponi ARIA (IV golimumab) for the Treatment of polyarticular course juvenile idiopathic arthritis (pcJIA). News release

 

September 2020 - FDA Approves XELJANZ/XELJANZ (tofacitinib) Oral Solution for the Treatment of polyarticular course juvenile idiopathic arthritis (pcJIA). Press release

 

August 2020 - Canakinumab improves systemic juvenile idiopathic arthritis regardless of fever Healio

 

October 2019 - Accelerating Drug Development for Polyarticular Juvenile Idiopathic Arthritis (pJIA). View the speaker slides and video recordings.

 

April 2019 - FDA approves Benlysta (belimumab) for children with lupus who are five years old or above